论文部分内容阅读
目的探讨采用不同喹诺酮类药物治疗社区获得性肺炎(CAP)的临床疗效。方法 200例CAP患者,随机分为观察组与对照组,每组100例。观察组给予盐酸莫西沙星氯化钠注射液治疗,对照组给予左氧氟沙星氯化钠注射液治疗。观察并对比两组患者的临床表现恢复时间、细菌清除率、不良反应发生率。结果观察组体温恢复正常时间、咳嗽消失时间、血常规恢复正常时间、胸部阴影吸收>50%时间均明显短于对照组(P<0.05);观察组细菌清除率(99%)明显高于对照组(79%)(t=20.43,P<0.05);两组的不良反应发生率比较差异无统计学意义(P>0.05)。结论采用莫西沙星治疗CAP临床疗效明显优于左氧氟沙星,且安全性高,值得临床推广。
Objective To investigate the clinical efficacy of different quinolones in the treatment of community-acquired pneumonia (CAP). Methods 200 CAP patients were randomly divided into observation group and control group, with 100 cases in each group. The observation group was given moxifloxacin hydrochloride sodium chloride injection, while the control group was given levofloxacin sodium chloride injection. The clinical manifestation recovery time, bacterial clearance rate and incidence of adverse reactions were observed and compared between the two groups. Results The body temperature recovery time, cough disappearance time, blood routine recovery time, chest shadow absorption> 50% were significantly shorter in the observation group than in the control group (P <0.05). The bacterial clearance rate in the observation group was significantly higher than that in the control group (79%) (t = 20.43, P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The clinical efficacy of moxifloxacin in the treatment of CAP is obviously better than that of levofloxacin, and it is safe and worthy of clinical promotion.